Herceptin News and Research

RSS

New research may help identify patients most likely to benefit from cisplatin treatment

Researchers at the Massachusetts General Hospital (MGH) Cancer Center have identified a subgroup of hard-to-treat breast cancers that may be sensitive to the drug cisplatin, rarely used in the treatment of breast tumors.

20 Apr 2007

Novel method to expand the number of immune system "natural killer" cells from blood cells outside the body

Researchers at the Kimmel Cancer Center at Jefferson in Philadelphia have devised a novel method to expand the number of immune system "natural killer (NK)" cells from blood cells outside the body.

19 Apr 2007

New discoveries about stem cells in leukemia, breast and colon cancer

Recent discoveries about the role of stem cells in cancer have altered the landscape of cancer research. With each new study, scientists are learning more about cancer-initiating properties of stem cells at organ sites and throughout the body.

19 Apr 2007

Scientists identify protein key to breast cancer spread

(PHILADELPHIA) Researchers at the Kimmel Cancer Center at Jefferson have identified a protein that they say is key to helping a quarter of all breast cancers spread.

10 Apr 2007

New role for sugars on proteins

In a ground-breaking study published in the top journal, Cell, Dr. James Dennis, senior investigator at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital, has discovered a new role for sugars on proteins.

7 Apr 2007

Although breast cancer mortality has declined as a whole, declines are greatest for women under 70

A new study shows that recent declines in breast cancer mortality rates have been most significant among women with estrogen receptor (ER)-positive tumors and women younger than 70.

4 Apr 2007

Tykerb (lapatinib) - new anti-cancer treatment approved

The Food and Drug Administration (FDA) has approved Tykerb (lapatinib), a new targeted anti-cancer treatment, to be used in combination with capectabine (Xeloda), another cancer drug, for patients with advanced, metastatic breast cancer that is HER2 positive (tumors that exhibit HER2 protein).

14 Mar 2007

Research defines the cancer role for protein Gab-2

A protein known for its ability to "bridge" interactions between other cellular proteins may spur metastasis in breast cancer, the disease's deadliest stage, a study from Burnham Institute for Medical Research has found.

22 Feb 2007

Researchers discover markers that identify breast cancer subtypes resistant to Herceptin

Using gene chips to profile tumors before treatment, researchers at Harvard and Yale Universities found markers that identified breast cancer subtypes resistant to Herceptin, the primary treatment for HER2-positive breast cancer. They say this advance could help further refine therapy for the 25 to 30 percent of breast cancer patients with this class of tumor.

20 Feb 2007

Battle looming between NHS and pharma giants

According to the Office of Fair Trading (OFT) in Britain, the National Health Service (NHS) is paying far too much to drug companies for branded medicines.

20 Feb 2007

Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging

Iron oxide nanoparticles have shown promise as agents for detecting tumors using magnetic resonance imaging (MRI), but such efforts have been limited by the relatively weak magnetic signal generated by these nanoparticles.

22 Jan 2007

Selective marker found to indicate aggressive form of breast cancer

Researchers have linked a structural protein called nestin to a particularly deadly form of breast cancer, identifying a new biomarker that could lead to earlier detection and better treatment.

16 Jan 2007

FDA expands use of Herceptin

The U.S. Food and Drug Administration (FDA) has expanded the approved use of Herceptin, a biological cancer drug. The new indication is for Herceptin, in combination with other cancer drugs, for the treatment of HER2 positive breast cancer after surgery (lumpectomy or mastectomy).

19 Nov 2006

Sequencing of chemotherapy and radiation therapy for early breast cancer

For women who have had surgery for early breast cancer, it may not matter whether they receive follow-up chemotherapy before, after or during radiation therapy, according to a new review of studies.

30 Oct 2006

Benefits of breast cancer screening questionable

Danish researchers are claiming that the benefits of breast cancer screening are questionable and that mammograms can lead to women being given unnecessary and harmful treatment.

18 Oct 2006

Roche asks European Medicines Agency for authorization to market Herceptin

Roche on Friday announced it has submitted an application with the European Medicines Agency to market its breast cancer drug Herceptin as a treatment for women living with an aggressive form of advanced-stage breast cancer, called HER2-positive, and hormone receptor-positive breast cancer, AFX/Forbes reports (AFX/Forbes, 10/13).

16 Oct 2006